News: Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni for the Treatment of Chronic HCV

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa®(sofosbuvir 400mg/velpatasvir 100mg) and Harvoni®(ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch Read more…